乳腺癌术后化疗期间血清CA153检测与其预后关系的研究  

Study on the Relationship between Serum CA153 of Postoperative Chemotherapy and Prognosis of Breast Cancer

作　　者：高建军[1] 王彬[1] 徐守森[1] 刘杰[1] 张玉海[1] 

机构地区：[1]潍坊市妇幼保健院乳腺外科,山东潍坊261011

出　　处：《医学综述》2011年第1期137-138,149,共3页Medical Recapitulate

摘　　要：目的探讨乳腺癌术后化疗3个疗程后血清乳腺癌相关抗原(CA153)不同界值对预后评估的意义。方法选取94例乳腺癌患者,在化疗3个疗程后进行血清CA153测定。分别取30、60和90U/mL为界值,以累计生存率和平均生存期为参数,绘制卡普兰-梅尔生存曲线,用时序检验法作预后分析。结果血清CA153≤30 U/mL组和>30 U/mL组患者累计生存率相比较,差异无统计学意义(P>0.05);≤60 U/mL组和>60 U/mL组患者累计生存率相比较,差异无统计学意义(P>0.05);≤90U/mL组和>90 U/mL组患者累计生存率相比较,差异有统计学意义(P<0.05)。结论血清CA153以90 U/mL为界值对预后评定有临床价值,对乳腺癌的预后有指导作用。Objective To investigate the significance of serum CA153 value taken after 3 cycle postoperative chemotherapy for evaluating the prognosis of breast cancer. Methods The patients were divided into three groups according to their serum CA153 concentration such as normal value（ 30 U/mL）, two fold of normal value （60 U/mL）and three fold of value （90 U/mL ） , respectively. Accumulated survival rate and average survival time were estimated using Kaplan-Meier estimates and compared with the lagrank test where indicated. Results Accumulated survival rate of patients whose 3 cycle postoperative chemotherapy semen CA153 were ≤ 30 U/mL had no significant difference（ P 〉 0.05 ） from that of CA153 〉 30 U/mL. There was no significant difference（P 〉0.05）between the group of CA153 ≤60 U/mL and 〉60 U/mL as well. Accumulated survival rate of patients whose 3 cycle postoperative chemotherapy serum CA153 490 U/mL was significantly higher than those whose CA153 〉 90 U/mL（ P 〈 0.05 ）. Conclusion 90 U/mL of CA153 after 3 cycle postoperative chemotherapy could be applied to evaluate prognosis of breast cancer.

关 键 词：乳腺癌 CA153 预后 

分 类 号：R392.1[医药卫生—免疫学]